Physician profile
Christopher Blake Ennis
NPI 1740739853
$3,250.58
in general payments reported to CMS, 2019-2025
24 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $643 · 2022: $1,372 · 2023: $665 · 2024: $316 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $682.02 | 2022-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $295.02 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $285.27 | 2021-2023 | Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.26 | 2021-2024 | Lifevest |
| Novo Nordisk INC | $195.16 | 2021-2023 | Rybelsus, Ozempic |
| Abbott Laboratories | $191.32 | 2022 | |
| Amgen INC. | $156.23 | 2021 | |
| Pfizer INC. | $146.90 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $146.85 | 2022-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $135.84 | 2021-2023 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $121.81 | 2021-2023 | Farxiga |
| Daiichi Sankyo INC. | $119.98 | 2022-2023 | Injectafer |
| Impulse Dynamics (USA) INC. | $107.14 | 2022-2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.40 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $82.48 | 2022-2023 | Camzyos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $48.81 | 2021-2022 | |
| United Therapeutics Corporation | $44.18 | 2022 | |
| Boston Scientific Corporation | $37.43 | 2021-2023 | Watchman Access System |
| Chiesi USA, INC. | $31.98 | 2024 | Cleviprex |
| Cvrx, INC. | $25.91 | 2023 | Barostim Neo System |
| Haemonetics Corporation | $25.25 | 2024 | Teg5000 Hemostasis Analyzer |
| Janssen Pharmaceuticals, INC | $14.00 | 2021 | |
| Amarin Pharma, INC. | $13.54 | 2021 | |
| Kestra Medical Technology Services, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.